CD40 and neoplasm: A phase I trial that took place in 2024, however, combined the CD40 agonist MEDI5083 with durvalumab and showed only minimal efficacy (2.8% ORR) in advanced solid tumors with significant toxicity issues, including severe injection-site reactions and one death related to the side effects of MEDI5083 leading to the project’s termination despite its immunologic anti-tumor mechanism [92].